Sobi - Swedish Orphan Biovitrum AB (publ) dans l'actualité
Accès aux thérapies pour maladies rares
Tamtam a trouvé 20 articles récents sur Sobi - Swedish Orphan Biovitrum AB (publ).
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history
- Swedish Orphan Biovitrum AB (publ) (SOBI.ST) stock price, news, quote and history
- Swedish Orphan Biovitrum AB (publ) (OMXSTO:SOBI) Pays $75M As Innate Deal Becomes Effective
- Sobi and Innate announce partnership is now effective following completion of closing conditions
- Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Sobi has completed an issue of class C shares
- Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Lacutamab Moves Toward Planned Phase 3 Trial in Rare T-Cell Lymphoma
- Innate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell Lymphoma
- The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under an incentive programme
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Have Insiders Sold Swedish Orphan Biovitrum Shares Recently?
- Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma
- Have Insiders Sold Swedish Orphan Biovitrum Shares Recently?
- Guido Oelkers to step down as CEO of Sobi in the beginning of 2027
- Guido Oelkers to step down as CEO of Sobi in the beginning of 2027
Articles collectés par Tamtam et retenus lorsqu'ils portent sur l'entreprise, des plus récents aux plus anciens. Chacun renvoie à sa source.
Vous vendez à des entreprises comme Sobi - Swedish Orphan Biovitrum AB (publ) ?
Tamtam trouve les entreprises qui correspondent à votre client idéal, analyse chaque compte et vous dit qui contacter, et quand.
Trouver des entreprises similaires